Annovis Nears Full AD Enrollment Ahead of NDA Plans
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More